导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.06% | 2207/4773 |
| 近一周 | -2.27% | 1635/5462 |
| 近一月 | -5.66% | 3312/5421 |
| 近一季 | -13.20% | 3956/5209 |
| 近半年 | -7.59% | 3239/4920 |
| 近一年 | 3.51% | 1917/4366 |
| 近两年 | 76.31% | 860/2954 |
| 近三年 | 34.32% | 889/2253 |
| 成立以来 | 41.84% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.37% 1563/4961 |
20.33% 1234/5312 |
- - |
- - |
| 2025 | 29.99% 1357/4813 |
3.56% 1070/3635 |
2.21% 1756/4076 |
21.89% 1737/4524 |
0.75% 1796/4813 |
| 2024 | 6.00% 1795/3463 |
-5.88% 1965/2808 |
-8.39% 2230/3014 |
17.39% 1198/3129 |
4.73% 673/3463 |
| 2023 | -4.15% 667/2656 |
10.37% 370/2280 |
-2.56% 610/2385 |
-7.81% 1627/2515 |
-3.32% 656/2655 |
| 2022 | -22.95% 1101/2207 |
-18.08% 1298/1919 |
4.09% 1061/2016 |
-12.61% 743/2113 |
3.41% 698/2208 |
| 2021 | 15.56% 303/1822 |
-4.87% 893/1255 |
12.63% 323/1330 |
-0.23% 482/1466 |
8.09% 163/1822 |
| 2020 | 28.30% 563/1250 |
-1.21% 208/1028 |
20.90% 255/1067 |
4.97% 938/1164 |
2.33% 996/1184 |
| 2019 | 30.00% 490/1092 |
31.24% 209/739 |
-11.29% 765/788 |
3.21% 264/850 |
8.19% 339/918 |
| 2018 | - - |
- - |
-15.91% 540/631 |
-11.41% 581/660 |
-11.92% 383/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中创400ETF联接C VS. 长安沪深300非周期A(740101) |